144 related articles for article (PubMed ID: 23978023)
21. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
23. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
24. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
[TBL] [Abstract][Full Text] [Related]
25. Detection of t(2;5)(p23;q35) in anaplastic large-cell lymphoma by long-range nested polymerase chain reaction assay.
Yin CC; Luthra R
Methods Mol Biol; 2013; 999():217-22. PubMed ID: 23666701
[TBL] [Abstract][Full Text] [Related]
26. Immunohistopathological features of anaplastic large-cell lymphoma according to anaplastic lymphoma kinase expression and bone marrow involvement pattern.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Histopathology; 2013 Jul; 63(1):13-8. PubMed ID: 23656317
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
28. Detection of the NPM-ALK genomic rearrangement of Ki-1 lymphoma and isolation of the involved NPM and ALK introns.
Ladanyi M; Cavalchire G
Diagn Mol Pathol; 1996 Sep; 5(3):154-8. PubMed ID: 8866227
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.
Salaverria I; Beà S; Lopez-Guillermo A; Lespinet V; Pinyol M; Burkhardt B; Lamant L; Zettl A; Horsman D; Gascoyne R; Ott G; Siebert R; Delsol G; Campo E
Br J Haematol; 2008 Mar; 140(5):516-26. PubMed ID: 18275429
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
31. [Anaplastic lymphoma kinase gene abnormality and the expression of its fusion protein in primary systemic anaplastic large cell lymphoma].
Shi YF; Liu CL; Zhou CJ; Gong LP; Dong LN; Li M; Huang X; Gao ZF
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):380-6. PubMed ID: 18677384
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
Hematol Oncol; 2009 Dec; 27(4):161-70. PubMed ID: 19358142
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
[TBL] [Abstract][Full Text] [Related]
34. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma.
Waggott W; Lo YM; Bastard C; Gatter KC; Leroux D; Mason DY; Boultwood J; Wainscoat JS
Br J Haematol; 1995 Apr; 89(4):905-7. PubMed ID: 7772531
[TBL] [Abstract][Full Text] [Related]
35. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
36. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.
Kourentzi K; Crum M; Patil U; Prebisch A; Chavan D; Vu B; Zeng Z; Litvinov D; Zu Y; Willson RC
Sci Rep; 2020 Mar; 10(1):5078. PubMed ID: 32193476
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.
Li C; Takino H; Eimoto T; Ishida T; Inagaki A; Ueda R; Suzuki R; Yoshino T; Nakagawa A; Nakamura S; Inagaki H
Mod Pathol; 2007 Jun; 20(6):648-55. PubMed ID: 17464320
[TBL] [Abstract][Full Text] [Related]
38. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation.
Damm-Welk C; Klapper W; Oschlies I; Gesk S; Röttgers S; Bradtke J; Siebert R; Reiter A; Woessmann W
Br J Haematol; 2009 Aug; 146(3):306-9. PubMed ID: 19545284
[TBL] [Abstract][Full Text] [Related]
39. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
40. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Dirks WG; Zaborski M; Jäger K; Challier C; Shiota M; Quentmeier H; Drexler HG
Leukemia; 1996 Jan; 10(1):142-9. PubMed ID: 8558920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
